Results 221 to 230 of about 218,171 (299)

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

Identification of Symptom Clusters and Core Symptoms in Inflammatory Bowel Disease: A Network Analysis in Chinese Cohorts. [PDF]

Gastroenterol Res Pract
Zhong Z, Luo Y, Xie Q, Xie X, Zhao R.
europepmc   +1 more source

ULCERATIVE COLITIS

Annals of Surgery, 1928
openaire   +3 more sources

Rapidly Progressive Cutaneous Nodules in an Elderly Woman

JEADV Clinical Practice, EarlyView.
Valeria Olvera‐Rodriguez, Gerardo González‐Martínez, Marion Carolina Alemán‐Jiménez, Minerva Gómez‐Flores, Jorge Ocampo‐Candiani, Lucía T. Fernández   +5 more
wiley   +1 more source

Characteristics, properties and limitations of per‐ or polyfluoroalkyl substances (PFASs) and fluoropolymers

Polymer International, EarlyView.
An overview and categorization of man‐made per‐ or polyfluoroalkyl substances (PFASs) including low‐molar‐mass and high‐molar‐mass fluorochemicals, and their international regulations is presented. Though certain PFASs are toxic, bioaccumulative and cross the human cellular membranes, others, such as fluoropolymers, are safe, reliable and involved in ...
Bruno Améduri
wiley   +1 more source

Bronchiectasis associated with ulcerative colitis relapse after lung transplantation: a case report. [PDF]

ERJ Open Res
Nassurally F, Pencreach E, Hirschi S, Vallat L, Rimelen V, Dégot T, Furstenberger M, Rahli M, Kessler R, Falcoz PE, Olland A, Tacquard C, Chenard MP, Renaud-Picard B.   +13 more
europepmc   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

ChatGPT-Assisted Image Interpretation for Inflammatory Bowel Diseases: Ulcerative Colitis and Crohn's Disease. [PDF]

JGH Open
Uekado H, Watanabe D, Aoyama Y, Kawase H, Ikeda S, Shiraki A, Pajimna J, Agawa M, Nakamura H, Ito Y, Okamoto N, Miyazaki H, Ku Y, Ooi M, Hoshi N, Kodama Y.   +15 more
europepmc   +1 more source

Redefining “Comorbidity” in Dermatology: Beyond Terminology, Lessons From Other Specialties

JEADV Clinical Practice, EarlyView.
Patricia Garbayo‐Salmons, Mireia Moreno   +1 more
wiley   +1 more source